DIRS.INFO The most relevant business & tech news

☆ This pharma stock is a buy as valuation remains attractive, Evercore says
▼ + stars: | 2023-09-19 | by ( Brian Evans | ) www.cnbc.com time to read: +1 min

Investors should pounce on CVS' current attractive valuation, according to Evercore ISI. The firm upgraded the health and pharmacy stock to outperform from in-line in a Tuesday note, accompanied by an $83 per share price target up from $81. CVS stock has slipped more than 24% from the start of the year. CVS YTD mountain CVS stock. "CVS, like many [managed care organizations], is a complex organization, and we see a number of factors swinging in a positive direction, pointing to both a higher degree of confidence in [management's] outlook as well as supportive of higher valuation," Anderson said.

Persons: Elizabeth Anderson, Anderson, CNBC's Michael Bloom Organizations: CVS, ISI, Centers, Medicare, Services

CVS Health logo is seen displayed in this illustration taken, May 3, 2022. The regional health insurance provider will still retain CVS Caremark for managing specialty drugs, which are costly medications used to treat complex conditions like cancer and rheumatoid arthritis. Other analysts highlighted difficulties in shifting to a different model than the one offered by companies like CVS - which provide other services including home drug delivery and reimburse pharmacies for patients' prescriptions. Amazon Pharmacy will provide at-home delivery of prescription drugs as well as upfront pricing, while Mark Cuban Cost Plus Drug Company will provide access to generic drugs, Blue Shield said. Blue Shield of California's other partners include privately held Abarca for processing claims related to prescription drugs, while smaller PBM Prime Therapeutics will work to negotiate savings with drugmakers.

Persons: Dado Ruvic, Cigna, UnitedHealth, Mark, Elizabeth Anderson, J.P, Morgan, Lisa Gill, Gill, Blue, Manas Mishra, Mariam Sunny, Bhanvi, Shweta Agarwal, Pooja Desai, Krishna Chandra Eluri, Frances Kerry Organizations: CVS, REUTERS, Amazon, Cigna, UnitedHealth, Evercore ISI, Mark Cuban, Plus, Thomson Locations: Bengaluru

☆ Amazon launches $5-a-month unlimited prescription plan
▼ + stars: | 2023-01-24 | by ( Nathaniel Meyersohn | ) edition.cnn.com time to read: +3 min

New York CNN —Amazon is expanding its push into healthcare with a $5 monthly unlimited delivery pass on 60 common generic prescription drugs treating allergies, inflammation, high blood pressure and other conditions. Amazon announced the new delivery service, RXPass, on Tuesday and it will launch immediately in most states except California, Texas, Minnesota and others with specific prescription delivery requirements. The $5-a-month delivery pass is an add-on to Amazon Prime, Amazon’s $139 annual program, and is available exclusively to Prime subscribers regardless of their insurance status. Amazon has long offered a Prime prescription savings benefit to get discounts on generic and brand-name medications. Amazon’s new plan will mean consumers may see lower costs for some generic drugs, Nicholson said.

Nov 2 (Reuters) - CVS Health Corp (CVS.N) on Wednesday forecast a 2023 profit below Wall Street estimates and said it hoped to mitigate the hit from a performance rating decline for its most popular Medicare plan by encouraging members to shift to other plans. read more CVS took a pre-tax charge of $5.2 billion in the third quarter related to the settlement. The settlement price, which was below investor expectations, according to Evercore ISI analyst Elizabeth Anderson, and other measures announced by the company helped lift CVS Health shares nearly 5%. In its insurance business, CVS said it is trying to move members out of Aetna's National PPO plan, which currently accounts for 59% of its Medicare Advantage plan members. CVS' health insurance business as well as peers Elevance Health (ELV.N) and UnitedHealth (UNH.N) have benefited from a slow recovery in elective procedures and a fall in COVID cases that has kept costs in check.

☆ CVS Health lifts forecast as PBM, insurance units drive profit beat
▼ + stars: | 2022-11-02 | by ( ) www.reuters.com time to read: +2 min

Nov 2 (Reuters) - CVS Health Corp (CVS.N) on Wednesday raised its annual profit forecast after topping quarterly estimates on strong performance at its health insurance and pharmacy benefit management businesses, sending its shares up 1% in premarket trade. CVS' health insurance business benefited from a slow recovery in elective procedures and a fall in COVID cases, which kept costs in check, as did peers Elevance Health (ELV.N) and UnitedHealth (UNH.N). Revenue from the insurance and pharmacy benefit management businesses rose around 10% each, while retail and pharmacy sales gained about 7%. Excluding some one-off items, CVS Health reported a profit of $2.09 per share, compared with analysts' average estimate of $1.99 per share. It removes an "overhang" on CVS and is lower than investor expectations, Evercore ISI analyst Elizabeth Anderson said in a note.

☆ Walgreens boosted by higher retail sales, nascent consumer health business
▼ + stars: | 2022-10-13 | by ( ) www.reuters.com time to read: +2 min

REUTERS/Andrew Kelly/File PhotoOct 13 (Reuters) - Walgreens Boots Alliance Inc (WBA.O) reported a better-than-expected quarterly profit on Thursday, as higher UK retail sales and strength in its newly launched consumer health business helped offset waning COVID vaccination demand. Shares of Walgreens, one of the largest U.S. pharmacies, rose nearly 7% in premarket trading after the company also forecast a higher full-year profit. Evercore ISI analyst Elizabeth Anderson said though the results were mixed, the full-year forecast was "much better than feared". The company also benefited from its Walgreens Health segment, which was launched last year as part of Walgreens' efforts to diversify its business. For 2023, Walgreens said its expects strong growth in its core business to offset waning demand for COVID related products and services.

Search resuls for: "Elizabeth Anderson"

6 mentions found